04:17 PM EDT, 10/08/2025 (MT Newswires) -- Ascendis Pharma ( ASND ) said late Wednesday it submitted a marketing authorization application to the European Medicines Agency for TransCon CNP, or navepegritide, to treat children with achondroplasia, a rare genetic bone disorder.

The application is based on data from three clinical trials, which showed that TransCon CNP was "generally" well tolerated, the company said.

The investigational drug is under priority review by the US Food and Drug Administration, with a Prescription Drug User Fee Act target date of Nov. 30, the company said.